A self-charging salt water battery for antitumor therapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Implantable devices on the tumor tissue as a local treatment are able to work in situ, which minimizes systemic toxicities and adverse effects. Here, we demonstrated an implantable self-charging battery that can regulate tumor microenvironment persistently by the well-designed electrode redox reaction. The battery consists of biocompatible polyimide electrode and zinc electrode, which can consume oxygen sustainably during battery discharge/self-charge cycle, thus modulating hypoxia level in tumor microenvironment. The oxygen reduction in battery leads to the formation of reactive oxygen species, showing 100% prevention on tumor formation. Sustainable consumption of oxygen causes adequate intratumoral hypoxic conditions over the course of 14 days, which is helpful for the hypoxia-activated prodrugs (HAPs) to kill tumor cells. The synergistic effect of the battery/HAPs can deliver more than 90% antitumor rate. Using redox reactions in electrochemical battery provides a potential approach for the tumor inhibition and regulation of tumor microenvironment.

Abstract

A biocompatible salt water battery was proposed to modulate tumor microenvironment for effective cancer therapy.

Related collections

Most cited references 62

Record: found
Abstract: found
Article: not found

Cancer Statistics, 2021

Rebecca Siegel, Kimberly D Miller, Hannah Fuchs … (2021)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.

0 comments Cited 7115 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Microenvironmental regulation of tumor progression and metastasis.

Daniela F Quail, Johanna A Joyce (2013)

Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence. However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis. Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer. Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.

0 comments Cited 2032 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Delivery technologies for cancer immunotherapy

Rachel S Riley, Carl H. June, Robert C Langer … (2019)

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding howto increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.

0 comments Cited 776 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Jianhang Huang:

ORCID: https://orcid.org/0000-0002-1471-0770

Role: ConceptualizationRole: Data curationRole: Formal analysisRole: Funding acquisitionRole: InvestigationRole: Project administrationRole: ValidationRole: VisualizationRole: Writing - original draft

Peng Yu: Role: ConceptualizationRole: Formal analysisRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: ResourcesRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing

Mochou Liao:

ORCID: https://orcid.org/0000-0001-6648-2506

Role: Funding acquisition

Xiaoli Dong:

ORCID: https://orcid.org/0000-0002-3267-7548

Role: InvestigationRole: Resources

Jie Xu:

ORCID: https://orcid.org/0000-0002-1579-0338

Role: Formal analysisRole: InvestigationRole: ValidationRole: Visualization

Jiang Ming:

ORCID: https://orcid.org/0000-0002-9375-5730

Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: MethodologyRole: VisualizationRole: Writing - original draftRole: Writing - review & editing

Duan Bin: Role: Formal analysis

Yonggang Wang:

ORCID: https://orcid.org/0000-0002-2447-4679

Role: ConceptualizationRole: Writing - original draft

Fan Zhang:

ORCID: https://orcid.org/0000-0001-7886-6144

Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: SupervisionRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing

Yongyao Xia:

ORCID: https://orcid.org/0000-0001-6379-9655

Role: ConceptualizationRole: Funding acquisitionRole: Project administrationRole: ResourcesRole: Supervision

Journal

Journal ID (nlm-ta): Sci Adv

Journal ID (iso-abbrev): Sci Adv

Journal ID (publisher-id): sciadv

Journal ID (hwp): advances

Title: Science Advances

Publisher: American Association for the Advancement of Science

ISSN (Electronic): 2375-2548

Publication date Collection: March 2023

Publication date (Electronic, pub): 31 March 2023

Volume: 9

Issue: 13

Electronic Location Identifier: eadf3992

Affiliations

[ ¹ ]Department of Chemistry and Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, iChEM (Collaborative Innovation Center of Chemistry for Energy Materials), Fudan University, Shanghai 200433, China.

[ ² ]Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, College of Chemistry and Materials Science, Zhejiang Normal University, Jinhua 321004, China.

Author notes

[* ]Corresponding author. Email: zhang_fan@ 123456fudan.edu.cn (F.Z.); yyxia@ 123456fudan.edu.cn (Y.X.)

[]

† These authors contributed equally to this work.

Author information

Jianhang Huang https://orcid.org/0000-0002-1471-0770

Mochou Liao https://orcid.org/0000-0001-6648-2506

Xiaoli Dong https://orcid.org/0000-0002-3267-7548

Jie Xu https://orcid.org/0000-0002-1579-0338

Jiang Ming https://orcid.org/0000-0002-9375-5730

Yonggang Wang https://orcid.org/0000-0002-2447-4679

Fan Zhang https://orcid.org/0000-0001-7886-6144

Yongyao Xia https://orcid.org/0000-0001-6379-9655

Article

Publisher ID: adf3992

DOI: 10.1126/sciadv.adf3992

PMC ID: 10065443

PubMed ID: 37000876

SO-VID: 8961ac9f-e384-4570-9ec1-c2d3073414e0

Copyright © Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

License:

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.